Olaparix (Olaparib 150mg)

Olaparix (Olaparib 150mg) is the best generic poly polymerase inhibitor indicated for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy and the first PARP inhibitor to gBRCAm metastatic breast cancer.

Olaparib Cost

Olaparib cost is about 13500USD per month. Generic Olaparib price in India online pharmacy is only 10% of the brand one.

Ovarian cancer

1.for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

2.for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynib | Olaparib 100mg.

Breast cancer

in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynib | Olaparib 100mg.

Olaparib dose

 1.Recommended tablet dose is 300 mg taken orally twice daily with or without food.

2. For adverse reactions, consider dose interruption or dose reduction.

3.For moderate renal impairment (CLcr 31-50 mL/min), reduce dose to 200 mg twice daily.

Olaparib Side Effects:

Olaparib may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).

Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with Lynparza. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Lynparza.

Symptoms of low blood cell counts are common during treatment with Lynparza, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include:

weakness weight loss fever frequent infections

• blood in urine or stool • shortness of breath • feeling very tired • bruising or bleeding more easily

Your healthcare provider will do blood tests to check your blood cell counts:

before treatment with Lynparza

every month during treatment with Lynparza

weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with Lynparza until your blood cell counts improve.

Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

Olaparib PI

For more Prescribing information，please ask for “FDA Prescribing Information” from our customer support.